Kraus Courtney L, Culican Susan M
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.
Int J Rheumatol. 2012;2012:203819. doi: 10.1155/2012/203819. Epub 2011 Dec 15.
Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated with rheumatic conditions may present with a wide range of signs and symptoms. This coexisting pathology should not be overlooked and should be considered a reason for initiation or continuation of biologic therapy. Additionally, many of the ocular manifestations of rheumatic disease respond preferentially to specific targeting molecules. This paper summarizes the available studies on the use, efficacy, and safety of biologic agents in the treatment of ocular manifestations of rheumatic disease.
生物制剂极大地改变了风湿性疾病的治疗模式。使用这些药物可以减轻疾病负担，使患者能够停用皮质类固醇，并降低复发的可能性。与风湿性疾病相关的眼部疾病可能表现出广泛的体征和症状。这种并存的病理情况不应被忽视，应被视为启动或继续生物治疗的一个理由。此外，风湿性疾病的许多眼部表现对特定的靶向分子有优先反应。本文总结了关于生物制剂在治疗风湿性疾病眼部表现方面的应用、疗效和安全性的现有研究。
